Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Updated Trends in Incidence and Survival of Mantle Cell Lymphoma from 2000 to 2020

Ruby Arora, John Lefante, Nakhle S. Saba

Blood (2023) 142 (Supplement 1): 5160.

https://doi.org/10.1182/blood-2023-190022

Published: 2023

Journal Articles

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn

Blood (2022) 140 (Supplement 1): 6635–6637.

https://doi.org/10.1182/blood-2022-162447

Published: 2022

Journal Articles

Use of FLAG+Venetoclax As Consolidation/Bridge to HSCT in Patients with Acute Myeloid Leukemia

Aneesha Ananthula, Dharmini Manogna, Sree Lanka, Katharine Thomas, Hana Safah, Nakhle S. Saba, Francisco Socola

Blood (2022) 140 (Supplement 1): 11734–11735.

https://doi.org/10.1182/blood-2022-168272

Published: 2022

Journal Articles

COVID-19 Immune Response in Hematologic Malignancies: Analysis of COVID-19 Anti-Spike Antibodies in Previously Infected and Uninfected Patients

Alex Niu, Victor H Ramirez, Bronwyn Gunn, Melyssa Bratton, Sarah Foster, James Robinson, Sree Lanka, Hana Safah, Francisco Socola, Yunwen Huang, Crystal Y Zheng, Ivy V Trinh, Amelie E Murrell, Jeffrey G Shaffer, Elizabeth B Norton, Nakhle S. Saba

Blood (2022) 140 (Supplement 1): 8351–8353.

https://doi.org/10.1182/blood-2022-165019

Published: 2022

Journal Articles

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel

Blood (2021) 138 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2021-147567

Published: 2021

Journal Articles

COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141578

Published: 2020

Journal Articles

COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Alex Niu, MD, Bo Ning, PhD, Francisco Socola, MD, Hana Safah, MD, Tim Reynolds, Moayed Ibrahim, MD, Firas Safa, MD, Tina Alfonso, Alfred Luk, MD, David M Mushatt, MD, Tony Hu, PhD, Nakhle S. Saba, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138611

Published: 2020

Journal Articles

Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351

Meagan A. Jacoby, Laura E. Finn, MD, Ashkan Emadi, MD, PhD, Nakhle S. Saba, MD, Bayard L. Powell, MD, Karen P. Seiter, MD, Rosella Garcia, Stefan Faderl, Heather J. Male

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-136880

Published: 2020

Journal Articles

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Nakhle S. Saba, MD, Jade Meyers, Lorena Fontan, PhD, Ari Melnick, MD, Adrian Wiestner, MD PhD, Patricia Lobelle-Rich, Ekaterina Kim, MS, Jan A. Burger, MD PhD, Yara Mouawad, MD, Prescott L. Deininger, PhD, Francisco Socola, MD, Hana Safah, MD, Erik K Flemington, PhD

Blood (2019) 134 (Supplement_1): 1288.

https://doi.org/10.1182/blood-2019-131376

Published: 2019

Journal Articles

Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma

John Xie, MD, Motohide Uemura, MD PhD, Shigeaki Nakazawa, MD PhD, Teresa Calimeri, MD PhD, Andres JM Ferreri, MD, Francisco Socola, MD, Hana Safah, MD, Nakhle S. Saba, MD

Blood (2019) 134 (Supplement_1): 2908.

https://doi.org/10.1182/blood-2019-129158

Published: 2019

Journal Articles

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Nakhle S. Saba, MD, A. Nicole Lucas, RN, Allison Jacob, MS, Erik Yusko, PhD, Seth M. Steinberg, PhD, Elaine S. Jaffe, Adrian Wiestner, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2018) 132 (Supplement 1): 147.

https://doi.org/10.1182/blood-2018-99-112573

Published: 2018

Journal Articles

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Hannah R. Robinson, Junpeng Qi, Erika M. Cook, Cydney Nichols, Eman L. Dadashian, Chingiz Underbayev, Sarah E. M. Herman, Nakhle S. Saba, Keyvan Keyvanfar, Clare Sun, Inhye E. Ahn, Sivasubramanian Baskar, Christoph Rader, Adrian Wiestner

Blood (2018) 132 (5): 521–532.

https://doi.org/10.1182/blood-2018-02-830992

Published: 2018

Includes: Supplemental data

Journal Articles

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood (2018) 131 (21): 2357–2366.

https://doi.org/10.1182/blood-2017-12-820910

Published: 2018

Includes: Supplemental data

Journal Articles

Tetraploidy in Acute Myeloid Leukemia Is Associated with Poor Outcomes Regardless of the Presence of Favorable Risk Features, and Requires an Allogeneic Stem Cell Transplant in First Remission

Bachir Berbari, MD, Matthew E. Behrens, Lindsey J. Hathaway, MD, Bachir Farah, MD, Ali Baghian, MD, Georges E. Tanios, MD, Theresa C. Brown, PhD, John J. Schmieg, MD PhD, Hana Safah, MD, Nakhle S. Saba, MD

Blood (2017) 130 (Supplement 1): 1308.

https://doi.org/10.1182/blood.V130.Suppl_1.1308.1308

Published: 2017

Journal Articles

CD5-Negative Mantle Cell Lymphoma Defines a Distinct Disease Entity Characterized By an Indolent Clinical Course Irrespective of Known Prognostic Markers

Arshia Soleimani, MD, John J. Schmieg, MD PhD, Theresa C. Brown, PhD, Lei Yin, MS Candidate, Hana Safah, MD, Nakhle S. Saba, MD

Blood (2017) 130 (Supplement 1): 4061.

https://doi.org/10.1182/blood.V130.Suppl_1.4061.4061

Published: 2017

Journal Articles

Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia

Clare Sun, MD, Delong Liu, PhD, Nakhle S. Saba, MD, Sarah E. M. Herman, PhD, Mehdi Pirooznia, MD PhD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 1718.

https://doi.org/10.1182/blood.V130.Suppl_1.1718.1718

Published: 2017

Journal Articles

Primary Dural Diffuse Large B-Cell Lymphoma Is Associated with Good Prognosis and Is Effectively Treated with CHOP-R Alone

Zachary L. Quinn, MD, Karam Zakharia, MD, Lei Yin, MS Candidate, Theresa C. Brown, PhD, John J. Schmieg, MD PhD, Hana Safah, MD, Nakhle S. Saba, MD

Blood (2017) 130 (Supplement 1): 4166.

https://doi.org/10.1182/blood.V130.Suppl_1.4166.4166

Published: 2017

Journal Articles

Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF-κb Pathway in Chronic Lymphocytic Leukemia Primary Cells

Georges Tanios, MD, Patricia Lobelle-Rich, Ashwin Vasudevamurthy, MD, Thomas S. Atkinson, MD, Ali Baghian, MD, Delong Liu, PhD, Hana Safah, MD, Erik K. Flemington, PhD, Nakhle S. Saba, MD

Blood (2016) 128 (22): 1597.

https://doi.org/10.1182/blood.V128.22.1597.1597

Published: 2016

Journal Articles

A Systemic Review of CD5-Negative Mantle Cell Lymphoma Identifies Potential Clinical and Biological Implications

Arshia Soleimani, MD, Georges Tanios, MD, Hana Safah, MD, Nakhle S. Saba, MD

Blood (2016) 128 (22): 3048.

https://doi.org/10.1182/blood.V128.22.3048.3048

Published: 2016

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma

Ali Baghian, MD, Reinhold Munker, MD, Yordanka Koleva, MPH, Gunita Matharoo, MPH, Patricia Andrews, MPH, Ato Wright, MD PhD, Nakhle S. Saba, MD, Hana Safah, MD

Blood (2016) 128 (22): 4644.

https://doi.org/10.1182/blood.V128.22.4644.4644

Published: 2016

NARROW

Updated Trends in Incidence and Survival of Mantle Cell Lymphoma from 2000 to 2020

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Use of FLAG+Venetoclax As Consolidation/Bridge to HSCT in Patients with Acute Myeloid Leukemia

COVID-19 Immune Response in Hematologic Malignancies: Analysis of COVID-19 Anti-Spike Antibodies in Previously Infected and Uninfected Patients

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients

COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Tetraploidy in Acute Myeloid Leukemia Is Associated with Poor Outcomes Regardless of the Presence of Favorable Risk Features, and Requires an Allogeneic Stem Cell Transplant in First Remission

CD5-Negative Mantle Cell Lymphoma Defines a Distinct Disease Entity Characterized By an Indolent Clinical Course Irrespective of Known Prognostic Markers

Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia

Primary Dural Diffuse Large B-Cell Lymphoma Is Associated with Good Prognosis and Is Effectively Treated with CHOP-R Alone

Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF-κb Pathway in Chronic Lymphocytic Leukemia Primary Cells

A Systemic Review of CD5-Negative Mantle Cell Lymphoma Identifies Potential Clinical and Biological Implications

Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only